Return to independent living
A multi‐component delirium prevention intervention showed no clear difference in return to independent living compared with usual care (moderate certainty).
1 finding from 1 review
Inpatient mortality
It is very uncertain whether A multi‐component delirium prevention intervention changes inpatient mortality compared with usual care (very low certainty).
1 finding from 1 review
Incidence of delirium
It is very uncertain whether prophylactic cholinesterase inhibitor changes incidence of delirium DSM‐IV criteria, DSI, CAM, compared with placebo (very low certainty).
1 finding from 1 review
Duration of delirium ‐ not measured
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium
1 finding from 1 review
Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in any adverse event (combined: diarrhoea, urinary tract infection,… compared with placebo (moderate certainty).
1 finding from 1 review
ADL outcome · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Overall dementia severity (cognition and function combined) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Memory ‐ not measured · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
QoL · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Depressive symptoms · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Mental health outcomes · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
IADL · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Intervention not reported
Incident dementia ‐ not measured · adults with cognitive impairment/dementia and cognitively intact populations
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cognition (at 90 days): t‐MMSE score1 · adults with cognitive impairment/dementia and cognitively intact populations
1 finding from 1 review
Intervention not reported
Composite cognitive function6 (change over 16 weeks) · adults with cognitive impairment/dementia and cognitively intact populations
1 finding from 1 review
Intervention not reported
Mortality (at 3 to 4 months' · adults with cognitive impairment/dementia and cognitively intact populations
The intervention showed no clear difference in mortality (at 3 to 4 months' (moderate certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular events (at 3 to 4 months' · adults with cognitive impairment/dementia and cognitively intact populations
The intervention showed no clear difference in cardiovascular events (at 3 to 4 months' (low certainty).
1 finding from 1 review